Professor, Oncology, University of Texas Medical School at Houston
Oncology
Dr. Daniel J. Booser, MD
|
|
Give Review
Daniel Booser works in the field of Oncology. He graduated from Yale University School of Medicine. Yale University School of Medicine is one of the top medical schools in the US. Yale University School of Medicine has a rank of 7 in research and a 57 in primary care He over the years received 2 awards: "Regional Top Doctor" and "Super Doctor". Daniel Booser is also published. He has 85 publications published. The lastest publication: "A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.' Daniel J. Booser, MD accepts Medicare.
Publications
- Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast Cancer.
- Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast Cancer and impaired liver function secondary to hepatic metastases.
- Outcome of metastatic breast Cancer in selected women with or without deleterious BRCA mutations.
- Radiation dose escalation for loco-regional recurrence of breast Cancer after mastectomy.
- Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast Cancer.
- Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Bas...
- A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast Cancer.
- Genomic index of sensitivity to endocrine therapy for breast Cancer.
- A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given Orally in a 3-times-daily regimen to treat patients with recurrent metastatic ...
- Phase 2 trial of primary Systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexa...
- Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast Cancer.
- Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast Cancer.
- Residual risk of breast Cancer recurrence 5 years after adjuvant therapy.
- A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast Cancer: safety, efficacy, and biologic activ...
- Randomized trial of high-dose chemotherapy and autologous hematopoietic stem Cell support for high-risk primary breast carcinoma: follow-up at 12 years.
- Weekly paclitaxel improves pathologic complete remission in operable breast Cancer when compared with paclitaxel once every 3 weeks.
- Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized tr...
- Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast Carcinoma.
- Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem Cell transp...
- A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast Cancer.
- Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast Cancer.
- Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor ...
- A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast Cancer.
- Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast Cancer: preliminary data of a prospective randomized trial.
- Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast Carcinoma.
- Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast Cancer.
- Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast Cancer.
- Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast Cancer.
- Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast Cancer.
- A phase III trial of sequential adjuvant chemotherapy for operable breast Carcinoma: final analysis with 10-year follow-up.
- Gene expression profiles obtained from fine-needle aspirations of breast Cancer reliably identify routine prognostic markers and reveal large-scale molecular differenc...
- Women age < or = 35 years with primary breast Carcinoma: disease features at presentation.
- Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast Carcinoma.
- Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast Cancer.
- Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.
- Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast Cancer.
- A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic Breast ...
- Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast Cancer: long-term results.
- Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry.
- Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast Cancer.
- Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-Cell research in...
- Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast Cancer.
- Effect of training-sample size and classification difficulty on the accuracy of genomic predictors.
- Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast Cancer.
- Phase II trial of 10-EDAM in the treatment of metastatic breast Cancer.
- Determination of oestrogen-receptor status and ERBB2 status of breast Carcinoma: a gene-expression profiling study.
- Imatinib mesylate (Gleevec) in advanced breast Cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.
- Treatment of locally advanced breast Cancer.
- Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small Cell lung cancer.
- Combined chemoradiotherapy in limited-disease, inoperable non-small Cell lung cancer.
- Esophageal complications from combined chemoradiotherapy (cyclophosphamide + Adriamycin + cisplatin + XRT) in the treatment of non-small Cell lung cancer.
- G6PD Toronto.
- Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung Cancer.
- Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small Cell lung cancer.
- Chemotherapy for advanced adenocarcinoma and squamous Cell carcinoma of the lung with etoposide and cisplatin.
- Anthracycline antibiotics in Cancer therapy. Focus on drug resistance.
- Phase II study of deoxyspergualin in metastatic breast Cancer.
- The M. D. Anderson Cancer Center experience with Taxol in metastatic breast Cancer.
- Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study.
- Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast Cancer.
- Phase I trial of droloxifene in patients with metastatic breast Cancer.
- Combined modality treatment of stage III and inflammatory breast Cancer. M.D. Anderson Cancer Center experience.
- Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast Cancer.
- Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast Cancer.
- A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast Cancer.
- Management of breast Cancer during pregnancy using a standardized protocol.
- Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast Cancer.
- Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast Cancer: phase I results.
- Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with opera...
- Randomized trial of high-dose chemotherapy and blood Cell autografts for high-risk primary breast carcinoma.
- Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast Cancer: a phase II study.
- Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast Cancer.
- Combined modality treatment of locally advanced breast Carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy.
- Phase I study of liposomal annamycin.
- Phase II study of paclitaxel in patients with metastatic breast Carcinoma refractory to standard chemotherapy.
- Long-term results of combined-modality therapy for locally advanced breast Cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Ca...
- Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast Cancer.
- Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast Cancer.
- Canalicular stenosis Secondary to docetaxel (taxotere): a newly recognized side effect.
- Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast Cancer: cumulative toxicities limit dose escalation.
- Paclitaxel in the multimodality treatment for inflammatory breast Carcinoma.
- Canalicular stenosis Secondary to weekly docetaxel: a potentially preventable side effect.
- Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast Cancer.
- Bortezomib (VELCADE) in metastatic breast Cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.
Schools
Yale University
University Pitt Health Center Hosps
Toronto General Hospital
Montreal General Hospital
Princess Margaret Hospital
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- Super Doctor
Education
-
University of Pittsburgh Medical Center -
Yale University School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1801996152 | |
| NPPES Provider LastName | BOOSER | |
| NPPES Provider FirstName | DANIEL | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 853.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 96.0 | |
| Percent Opioid Claims | 11.25 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1801996152 |
| Last Name Of The Provider | BOOSER |
| First Name Of The Provider | DANIEL |
| View All |
Similar Doctors
|
|
Dr. Richard L. Theriault, DO |
|
|
Dr. Jianjun Gao, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dejka M. Araujo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachna Shroff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Overman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William N. William Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristy L. Richards, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edmund S. Kopetz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alessandra Ferrajoli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Celyne Bueno-Hume, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Teresa G. Hayes, MD |
|
|
Dr. John V. Heymach, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Ajay Mitter, MD
This Doctor is OpenDoctor Recommended.
|